SynthesisNeurosurgical review2020
IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Article
- IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.Neuro-oncology · 2022Article
- The persistence of seizures after tumor resection negatively affects survival in low-grade glioma patients: a clinical retrospective study.Journal of neurology · 2022Article
- The Concept of «Peritumoral Zone» in Diffuse Low-Grade Gliomas: Oncological and Functional Implications for a Connectome-Guided Therapeutic Attitude.Brain sciences · 2022Review
- The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study.Neuro-oncology · 2022Article
- Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications.Frontiers in oncology · 2022Review
- Pre- and Post-surgical Poor Seizure Control as Hallmark of Malignant Progression in Patients With Glioma?Frontiers in neurology · 2022Article
- BTBD10 inhibits glioma tumorigenesis by downregulating cyclin D1 and p-Akt.Open life sciences · 2022Article
- Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.Journal of neuro-oncology · 2021Article
- What Does Quality of Care Mean in Lower-Grade Glioma Patients: A Precision Molecular-Based Management of the Tumor or an Individualized Medicine Centered on Patient's Choices?Frontiers in oncology · 2021Article
- Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis.Journal of neurosurgery · 2020Article
- Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.AJNR. American journal of neuroradiology · 2020Article
- Postoperative oscillatory brain activity as an add-on prognostic marker in diffuse glioma.Journal of neuro-oncology · 2020Article
- Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.Frontiers in oncology · 2020Article
- Application of an Artificial Intelligence Algorithm to Prognostically Stratify Grade II Gliomas.Cancers · 2019Article
- IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.European journal of nuclear medicine and molecular imaging · 2019Article
- Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.AJNR. American journal of neuroradiology · 2019Article
- Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.Neuro-oncology practice · 2019Article
- V-ATPase expression in gliomas-Not your grandparents' proton pump.EBioMedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
WHO grade II diffuse low-grade gliomas (DLGGs) were recently divided into sub-groups on the basis of their molecular profiles. IDH wild-type (IDH-wt) tumors seem to be associated with unfavorable prognoses due to biological similarities to glioblastomas. The authors performed a systematic review and meta-analysis of literature examining epidemiology, clinical characteristics, management, and the outcome of IDH-wt grade II DLGGs. According to PRISMA guidelines, a comprehensive review of studies published from January 2009 to October 2017 was carried out. The authors identified series that examined the prevalence rate, clinical and radiological characteristics, treatment, and outcome of IDH-wt DLGGs. Variables influencing outcomes were analyzed using a random-effects meta-analysis model. Finally, a meta-regression analysis was performed to examine the impact of therapeutic strategies on the effect-size. Twenty-two studies were included in this systematic review. The IDH-wt prevalence rate was 22.9% (95% CI 18.4-27.4%). The hazard ratio for this molecular subgroup in the DLGGs population was 3.46 (95% CI 2.24-5.36; p < 0.001), and the heterogeneity was significant (I
Indexed as
Identifiers
29943141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.